|
1
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cummins DL, Cummins JM, Pantle H,
Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant
melanoma. Mayo Clin Proc. 81:500–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kato M, Liu W, Akhand AA, Hossain K,
Takeda K, Takahashi M and Nakashima I: Ultraviolet radiation
induces both full activation of ret kinase and malignant
melanocytic tumor promotion in RFP-RET-transgenic mice. J Invest
Dermatol. 115:1157–1158. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Libra M, Malaponte G, Navolanic PM,
Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino
MC, Travali S, et al: Analysis of BRAF mutation in primary and
metastatic melanoma. Cell Cycle. 4:1382–1384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hocker TL, Singh MK and Tsao H: Melanoma
genetics and therapeutic approaches in the 21st century: Moving
from the benchside to the bedside. J Invest Dermatol.
128:2575–2595. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsao H, Chin L, Garraway LA and Fisher DE:
Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Levy C, Khaled M and Fisher DE: MITF:
Master regulator of melanocyte development and melanoma oncogene.
Trends Mol Med. 12:406–414. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Du J, Widlund HR, Horstmann MA, Ramaswamy
S, Ross K, Huber WE, Nishimura EK, Golub TR and Fisher DE: Critical
role of CDK2 for melanoma growth linked to its melanocyte-specific
transcriptional regulation by MITF. Cancer Cell. 6:565–576. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buscà R, Berra E, Gaggioli C, Khaled M,
Bille K, Marchetti B, Thyss R, Fitsialos G, Larribère L, Bertolotto
C, et al: Hypoxia-inducible factor 1{alpha} is a new target of
microphthalmia-associated transcription factor (MITF) in melanoma
cells. J Cell Biol. 170:49–59. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McGill GG, Haq R, Nishimura EK and Fisher
DE: c-Met expression is regulated by Mitf in the melanocyte
lineage. J Biol Chem. 281:10365–10373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yasumoto K, Takeda K, Saito H, Watanabe K,
Takahashi K and Shibahara S: Microphthalmia-associated
transcription factor interacts with LEF-1, a mediator of Wnt
signaling. EMBO J. 21:2703–2714. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Price ER, Horstmann MA, Wells AG,
Weilbaecher KN, Takemoto CM, Landis MW and Fisher DE:
alpha-Melanocyte-stimulating hormone signaling regulates expression
of microphthalmia, a gene deficient in Waardenburg syndrome. J Biol
Chem. 273:33042–33047. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu M, Hemesath TJ, Takemoto CM, Horstmann
MA, Wells AG, Price ER, Fisher DZ and Fisher DE: c-Kit triggers
dual phosphorylations, which couple activation and degradation of
the essential melanocyte factor Mi. Genes Dev. 14:301–312.
2000.PubMed/NCBI
|
|
14
|
Bertolotto C, Abbe P, Hemesath TJ, Bille
K, Fisher DE, Ortonne JP and Ballotti R: Microphthalmia gene
product as a signal transducer in cAMP-induced differentiation of
melanocytes. J Cell Biol. 142:827–835. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beuret L, Flori E, Denoyelle C, Bille K,
Busca R, Picardo M, Bertolotto C and Ballotti R: Up-regulation of
MET expression by alpha-melanocyte-stimulating hormone and MITF
allows hepatocyte growth factor to protect melanocytes and melanoma
cells from apoptosis. J Biol Chem. 282:14140–14147. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jang SW, Liu X, Yepes M, Shepherd KR,
Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, et al: A
selective TrkB agonist with potent neurotrophic activities by
7,8-dihydroxyflavone. Proc Natl Acad Sci USA. 107:2687–2692. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen J, Chua KW, Chua CC, Yu H, Pei A,
Chua BH, Hamdy RC, Xu X and Liu CF: Antioxidant activity of
7,8-dihydroxyflavone provides neuroprotection against
glutamate-induced toxicity. Neurosci Lett. 499:181–185. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang R, Kang KA, Piao MJ, Ko DO, Wang ZH,
Chang WY, You HJ, Lee IK, Kim BJ, Kang SS, et al: Preventive effect
of 7,8-dihydroxyflavone against oxidative stress induced
genotoxicity. Biol Pharm Bull. 32:166–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han X, Zhu S, Wang B, Chen L, Li R, Yao W
and Qu Z: Antioxidant action of 7,8-dihydroxyflavone protects PC12
cells against 6-hydroxydopamine-induced cytotoxicity. Neurochem
Int. 64:18–23. 2014. View Article : Google Scholar
|
|
20
|
Lee RH, Shin JC, Kim KH, Choi YH, Chae JI
and Shim JH: Apoptotic effects of 7,8-dihydroxyflavone in human
oral squamous cancer cells through suppression of Sp1. Oncol Rep.
33:631–638. 2015.
|
|
21
|
Park HY, Kim GY, Hyun JW, Kim ND, Kim CG,
Kim WJ, Yoo YH and Choi YH: 7,8-dihydroxyflavone induces g1 arrest
of the cell cycle in U937 human monocytic leukemia cells via
induction of the Cdk inhibitor p27 and downregulation of pRB
phosphorylation. Oncol Rep. 28:353–357. 2012.PubMed/NCBI
|
|
22
|
Hunt G, Todd C, Cresswell JE and Thody AJ:
Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7
alpha-MSH affect morphology, tyrosinase activity and melanogenesis
in cultured human melanocytes. J Cell Sci. 107:205–211.
1994.PubMed/NCBI
|
|
23
|
Rusciano D, Lorenzoni P and Burger MM:
Regulation of c-met expression in B16 murine melanoma cells by
melanocyte stimulating hormone. J Cell Sci. 112:623–630.
1999.PubMed/NCBI
|
|
24
|
Poser I and Bosserhoff AK: Transcription
factors involved in development and progression of malignant
melanoma. Histol Histopathol. 19:173–188. 2004.PubMed/NCBI
|
|
25
|
Riley PA: Melanogenesis and melanoma.
Pigment Cell Res. 16:548–552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Costin GE and Hearing VJ: Human skin
pigmentation: Melanocytes modulate skin color in response to
stress. FASEB J. 21:976–994. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JH, Jang JY, Park C, Kim BW, Choi YH
and Choi BT: Curcumin suppresses alpha-melanocyte stimulating
hormone-stimulated melanogenesis in B16F10 cells. Int J Mol Med.
26:101–106. 2010.PubMed/NCBI
|
|
28
|
Jin SH, Lee YY and Kang HY:
Methyl-beta-cyclodextrin, a specific cholesterol-binding agent,
inhibits melanogenesis in human melanocytes through activation of
ERK. Arch Dermatol Res. 300:451–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gusman J, Malonne H and Atassi G: A
reappraisal of the potential chemopreventive and chemotherapeutic
properties of resveratrol. Carcinogenesis. 22:1111–1117. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen YJ, Chen YY, Lin YF, Hu HY and Liao
HF: Resveratrol inhibits alpha-melanocyte-stimulating hormone
signaling, viability, and invasiveness in melanoma cells. Evid
Based Complement Alternat Med. 2013:6321212013.PubMed/NCBI
|
|
31
|
Garraway LA, Widlund HR, Rubin MA, Getz G,
Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J,
et al: Integrative genomic analyses identify MITF as a lineage
survival oncogene amplified in malignant melanoma. Nature.
436:117–122. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Osmond GW, Augustine CK, Zipfel PA,
Padussis J and Tyler DS: Enhancing melanoma treatment with
resveratrol. J Surg Res. 172:109–115. 2012. View Article : Google Scholar
|
|
33
|
Fulda S and Debatin KM: Sensitization for
anticancer drug-induced apoptosis by the chemopreventive agent
resveratrol. Oncogene. 23:6702–6711. 2004. View Article : Google Scholar : PubMed/NCBI
|
